a Department of Gynaecological Oncology , Royal Surrey County Hospital , Guildford , UK.
b Department of Clinical and Experimental Medicine (Oncology Section), School Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey , Guildford , UK.
Acta Oncol. 2019 Mar;58(3):342-352. doi: 10.1080/0284186X.2018.1540886. Epub 2019 Jan 7.
Endometrial cancer is the most common gynaecological cancer and its incidence is rising due to increasing obesity rates. We are also seeing an increasing trend of young women diagnosed with either endometrial cancer or its precancerous state, endometrial hyperplasia. Diagnosis is dependent on invasive testing and there is no screening tool available for either general or high-risk population groups. Whilst vast amounts of research have been undertaken in higher-profile cancers such as ovarian and cervical, endometrial cancer is comparatively less investigated.
In this literature review, we summarise the existing literature in understanding the role of tumour biomarkers for endometrial cancer and its preceding condition of endometrial hyperplasia.
NICE Healthcare Databases Search tool was used to search Embase, Medline and PubMed databases for relevant articles.
There is currently no routinely used biomarker in endometrial cancer for diagnostic or prognostic purposes. Given the establishment of new genomic classifications of endometrial cancers, the use of biomarkers to drive therapeutic approaches will be the cornerstone for individualised cancer care in the coming decades.
子宫内膜癌是最常见的妇科癌症，由于肥胖率的上升，其发病率也在上升。我们也看到越来越多的年轻女性被诊断出患有子宫内膜癌或其癌前状态——子宫内膜增生。诊断依赖于有创性检测，目前尚无针对普通人群或高危人群的筛查工具。尽管在卵巢癌和宫颈癌等高知名度癌症方面进行了大量研究，但子宫内膜癌的研究相对较少。
在本次文献综述中，我们总结了目前关于肿瘤生物标志物在子宫内膜癌及其前体子宫内膜增生中的作用的文献。
使用 NICE 医疗保健数据库搜索工具在 Embase、Medline 和 PubMed 数据库中搜索相关文章。
目前尚无用于诊断或预后目的的常规子宫内膜癌生物标志物。鉴于新的子宫内膜癌基因组分类的建立，生物标志物的使用将成为未来几十年个体化癌症治疗的基石。
